174 related articles for article (PubMed ID: 33847305)
1. Increase in Body Mass Index in Children With HIV, Switched to Tenofovir Alafenamide Fumarate or Dolutegravir Containing Antiretroviral Regimens.
Yeoh DK; Campbell AJ; Bowen AC
Pediatr Infect Dis J; 2021 May; 40(5):e215-e216. PubMed ID: 33847305
[No Abstract] [Full Text] [Related]
2. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
[TBL] [Abstract][Full Text] [Related]
3. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens.
Cindi Z; Maartens G; Bradford Y; Venter WDF; Sokhela S; Chandiwana NC; Haas DW; Sinxadi P
J Acquir Immune Defic Syndr; 2021 Jul; 87(3):1002-1009. PubMed ID: 33625064
[TBL] [Abstract][Full Text] [Related]
4. Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.
Hoffman RM; Brummel S; Ziemba L; Chinula L; McCarthy K; Fairlie L; Jean-Philippe P; Chakhtoura N; Johnston B; Krotje C; Nematadzira TG; Nakayiwa F; Ndyanabangi V; Hanley S; Theron G; Violari A; João E; Correa MD; Hofer CB; Navanukroh O; Aurpibul L; Nevrekar N; Zash R; Shapiro R; Stringer JSA; Currier JS; Sax P; Lockman S;
Clin Infect Dis; 2024 Jun; 78(6):1617-1628. PubMed ID: 38180851
[TBL] [Abstract][Full Text] [Related]
5. Body Fat Distribution and Metabolic Changes in a Cohort of Adolescents Living With HIV Switched to an Antiretroviral Regimen Containing Dolutegravir.
Giacomet V; Lazzarin S; Manzo A; Paradiso L; Maruca K; Barera G; Zuccotti GV; Mora S
Pediatr Infect Dis J; 2021 May; 40(5):457-459. PubMed ID: 33847293
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
7. Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Calza L; Borderi M; Colangeli V; Miani T; Nuti B; Bon I; Lazzarotto T; Viale P
AIDS; 2022 Jan; 36(1):153-155. PubMed ID: 34873095
[No Abstract] [Full Text] [Related]
8. Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Boffito M; Waters L; Cahn P; Paredes R; Koteff J; Van Wyk J; Vincent T; Demarest J; Adkison K; Quercia R
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):13-18. PubMed ID: 31507204
[TBL] [Abstract][Full Text] [Related]
9. Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function.
Quesada-López T; Cereijo R; Blasco-Roset A; Mestres-Arenas A; Prieto P; Domingo JC; Villarroya F; Domingo P; Giralt M
Biochem Pharmacol; 2024 Feb; 220():116010. PubMed ID: 38154544
[TBL] [Abstract][Full Text] [Related]
10. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
[TBL] [Abstract][Full Text] [Related]
11. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
12. Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV.
Tempestilli M; D'Avolio A; De Nicolò A; Agrati C; Antinori A; Cicalini S
J Antimicrob Chemother; 2021 Nov; 76(12):3320-3322. PubMed ID: 34450632
[No Abstract] [Full Text] [Related]
13. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Stellbrink HJ; Arribas JR; Stephens JL; Albrecht H; Sax PE; Maggiolo F; Creticos C; Martorell CT; Wei X; Acosta R; Collins SE; Brainard D; Martin H
Lancet HIV; 2019 Jun; 6(6):e364-e372. PubMed ID: 31068272
[TBL] [Abstract][Full Text] [Related]
14. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
15. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E
Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499
[TBL] [Abstract][Full Text] [Related]
16. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM; Ward D; Brar I; Mills A; Stellbrink HJ; López-Cortés L; Ruane P; Podzamczer D; Brinson C; Custodio J; Liu H; Andreatta K; Martin H; Cheng A; Quirk E
Lancet HIV; 2018 Jul; 5(7):e357-e365. PubMed ID: 29925489
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir for second-line antiretroviral therapy: the beat goes on.
Shangase N; Kufa T
Lancet Glob Health; 2024 Feb; 12(2):e183-e184. PubMed ID: 38142693
[No Abstract] [Full Text] [Related]
18. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
[TBL] [Abstract][Full Text] [Related]
19. Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
Dorward J; Sookrajh Y; Lessells R; Bulo E; Bodley N; Singh L; Moodley P; Samsunder N; Drain PK; Hayward G; Butler CC; Garrett N
J Acquir Immune Defic Syndr; 2024 Apr; 95(5):e8-e11. PubMed ID: 38489494
[TBL] [Abstract][Full Text] [Related]
20. Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Fernvik E; Sierra Madero J; Espinosa N; Gulminetti R; Hagins D; Tsai HC; Man C; Sievers J; Grove R; Zolopa A; Wynne B; van Wyk J; Ait-Khaled M
J Acquir Immune Defic Syndr; 2023 Nov; 94(3):e9-e12. PubMed ID: 37850985
[No Abstract] [Full Text] [Related]
[Next] [New Search]
